{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:38:16Z","timestamp":1781163496076,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[1999,7,9]],"date-time":"1999-07-09T00:00:00Z","timestamp":931478400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[1999,8]]},"DOI":"10.1038\/sj.bjc.6690598","type":"journal-article","created":{"date-parts":[[2002,9,5]],"date-time":"2002-09-05T18:08:00Z","timestamp":1031249280000},"page":"1786-1791","source":"Crossref","is-referenced-by-count":27,"title":["Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II"],"prefix":"10.1038","volume":"80","author":[{"name":"for the CRC Phase I\/II Committee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Twelves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Flavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Sludden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J de","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Vasey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Macham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N M","family":"Bleehen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[1999,7,9]]},"reference":[{"key":"BF6690598_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/00001813-199602000-00004","volume":"7","author":"D Abigerges","year":"1996","unstructured":"Abigerges, D., Armand, J-P, Chabot, G. G., Bruno, R., Bissery, M-C, Bayssas, M., Klink-Alaki, M., Clavel, M. & Catimel, G. (1996). Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs 7: 166\u2013174.","journal-title":"Anticancer Drugs"},{"key":"BF6690598_CR2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1021\/jm00387a014","volume":"30","author":"GJ Atwell","year":"1987","unstructured":"Atwell, G. J., Rewcastle, G. W., Baguley, B. C. & Denny, W. A. (1987). Potential anti-tumour agents. 50. In vivo solid tumour activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664\u2013669.","journal-title":"J Med Chem"},{"key":"BF6690598_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/jnci\/82.5.398","volume":"82","author":"BC Baguley","year":"1990","unstructured":"Baguley, B. C., Holdaway, K. M. & Fray, L. M. (1990). Design of DNA intercalators to overcome topoisomerase II-mediated multi-drug resistance. J Natl Cancer Inst 82: 398\u2013402.","journal-title":"J Natl Cancer Inst"},{"key":"BF6690598_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/BF00685854","volume":"36","author":"BC Baguley","year":"1995","unstructured":"Baguley, B. C., Zhuang, L. & Marshall, E. (1995). Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother Pharmacol 36: 224\u2013248.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690598_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/BF00695991","volume":"31","author":"SMH Evans","year":"1992","unstructured":"Evans, S. M. H., Young, D., Robertson, I. G. C. & Paxton, J. W. (1992). Intraperitoneal administration of the anti-tumour agent of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. Cancer Chemother Pharmacol 31: 32\u201336.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690598_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0277-5379(89)90019-9","volume":"25","author":"GJ Finlay","year":"1989","unstructured":"Finlay, G. J. & Baguley, B. C. (1989). Selectivity of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol 25: 271\u2013277.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF6690598_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/BF00686155","volume":"31","author":"GJ Finlay","year":"1993","unstructured":"Finlay, G. J., Marshall, E., Matthews, J. H. L., Paul, K. D. & Baguley, B. C. (1993). In vitro assessment of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401\u2013406.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690598_CR8","first-page":"6404","volume":"48","author":"RS Gupta","year":"1988","unstructured":"Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J. & Johns, R. K. (1988). Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48: 6404\u20136410.","journal-title":"Cancer Res"},{"key":"BF6690598_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ijc.2910500420","volume":"50","author":"Y Kano","year":"1992","unstructured":"Kano, Y., Suzuki, K., Akatsu, M., Suda, K., Inoue, Y., Yoshida, M., Sakamoto, S. & Miura, Y. (1992). Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50: 604\u2013610.","journal-title":"Int J Cancer"},{"key":"BF6690598_CR10","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1200\/JCO.1993.11.10.2030","volume":"11","author":"A Karato","year":"1993","unstructured":"Karato, A., Saski, Y. & Shiraishi, J. et al (1993). Phase I study of CPT-11 and etoposide in patients with refractory solid tumours. J Clin Oncol 11: 2030\u20132035.","journal-title":"J Clin Oncol"},{"key":"BF6690598_CR11","first-page":"1129","volume":"51","author":"SH Kaufman","year":"1991","unstructured":"Kaufman, S. H. (1991). Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukaemia cell line. Cancer Res 51: 1129\u20131136.","journal-title":"Cancer Res"},{"key":"BF6690598_CR12","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/jnci\/84.5.340","volume":"84","author":"ES Marshall","year":"1992","unstructured":"Marshall, E. S., Finlay, G. J., Matthews, J. H. L., Shaw, J. H. F., Nixon, J. & Baguley, B. C. (1992). Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst 84: 340\u2013345.","journal-title":"J Natl Cancer Inst"},{"key":"BF6690598_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/BF00686007","volume":"29","author":"JW Paxton","year":"1992","unstructured":"Paxton, J. W., Young, D., Evans, S. M. H., Kestell, P., Robertson, I. G. C. & Cornford, E. M. (1992). Pharmacokinetics and toxicity of the anti-tumour agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol 29: 379\u2013384.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690598_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/BF00686179","volume":"32","author":"JW Paxton","year":"1993","unstructured":"Paxton, J. W., Young, D., Evans, S. M. H., Robertson, I. G. C. & Kestell, P. (1993a). Tumour profile of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse. Cancer Chemother Pharmacol 32: 320\u2013322.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690598_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00686180","volume":"32","author":"JW Paxton","year":"1993","unstructured":"Paxton, J. W., Young, D. & Robertson, I. G. C. (1993b). Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans. Cancer Chemother Pharmacol 32: 323\u2013325.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6690598_CR16","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/0277-5379(88)90082-X","volume":"24","author":"E Schneider","year":"1988","unstructured":"Schneider, E., Darkin, S. J., Lawson, P. A., Ching, L-M, Ralph, R. K. & Baguley, B. C. (1988). Cell line selectivity and DNA breakage properties of the anti-tumour agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol 24: 1783\u20131790.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF6690598_CR17","doi-asserted-by":"crossref","first-page":"9182","DOI":"10.1016\/S0021-9258(17)47282-6","volume":"259","author":"KM Tewey","year":"1984","unstructured":"Tewey, K. M., Chen, G. L., Nelson, E. M. & Liu, L. F. (1984). Intercalative antitumour drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 9182\u20139187.","journal-title":"J Biol Chem"},{"key":"BF6690598_CR18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1073\/pnas.85.5.1417","volume":"85","author":"DK Trask","year":"1988","unstructured":"Trask, D. K. & Muller, M. T. (1988). Stabalization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 85: 1417\u20131421.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6690598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690598","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6690598.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:54:47Z","timestamp":1684414487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6690598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,7,9]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1999,8]]}},"alternative-id":["BF6690598"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6690598","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,7,9]]}}}